KR101426238B1 - Herbal Extract For Preventing and Treating Disease of Oral Cavity - Google Patents
Herbal Extract For Preventing and Treating Disease of Oral Cavity Download PDFInfo
- Publication number
- KR101426238B1 KR101426238B1 KR1020130121685A KR20130121685A KR101426238B1 KR 101426238 B1 KR101426238 B1 KR 101426238B1 KR 1020130121685 A KR1020130121685 A KR 1020130121685A KR 20130121685 A KR20130121685 A KR 20130121685A KR 101426238 B1 KR101426238 B1 KR 101426238B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- content
- activity
- natural
- oral
- Prior art date
Links
- 230000003405 preventing effect Effects 0.000 title claims description 5
- 210000000214 mouth Anatomy 0.000 title description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 201000010099 disease Diseases 0.000 title description 4
- 239000012676 herbal extract Substances 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 71
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 31
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 23
- 208000025157 Oral disease Diseases 0.000 claims abstract description 19
- 208000030194 mouth disease Diseases 0.000 claims abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 16
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 16
- 238000011088 calibration curve Methods 0.000 claims description 13
- 230000002292 Radical scavenging effect Effects 0.000 claims description 12
- 229930003935 flavonoid Natural products 0.000 claims description 10
- 150000002215 flavonoids Chemical class 0.000 claims description 10
- 235000017173 flavonoids Nutrition 0.000 claims description 10
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 9
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 9
- 235000005493 rutin Nutrition 0.000 claims description 9
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 9
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 9
- 229960004555 rutoside Drugs 0.000 claims description 9
- 235000004515 gallic acid Nutrition 0.000 claims description 8
- 229940074391 gallic acid Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000009036 growth inhibition Effects 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241001505935 Phalaenopsis Species 0.000 claims 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims 1
- 229940042125 oral ointment Drugs 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000005445 natural material Substances 0.000 abstract description 10
- 241000894006 Bacteria Species 0.000 description 16
- 208000028169 periodontal disease Diseases 0.000 description 14
- 240000004371 Panax ginseng Species 0.000 description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 235000008434 ginseng Nutrition 0.000 description 11
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 6
- 241001480065 Quercus serrata Species 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000016071 Cordyline australis Nutrition 0.000 description 4
- 244000225789 Cordyline australis Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002064 Dental Plaque Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- -1 convergence Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 240000004950 Artemisia lactiflora Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 235000008496 Drimys aromatica Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241001595563 Gabbia Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 235000001577 Lindera glauca Nutrition 0.000 description 1
- 244000245109 Lindera glauca Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034535 Periodontal destruction Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000582770 Salvelinus neiva Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000329195 Sparganium erectum Species 0.000 description 1
- 241001180441 Sparganium stoloniferum Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- OAOSXODRWGDDCV-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine;4-methylbenzenesulfonic acid Chemical compound CN(C)C1=CC=NC=C1.CC1=CC=C(S(O)(=O)=O)C=C1 OAOSXODRWGDDCV-UHFFFAOYSA-N 0.000 description 1
- 238000010417 needlework Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 235000012420 sanguinaria Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 천연물 소재로부터 분리한 구강질환 예방 및 치료용 활성을 가진 추출물로서, 스트렙토코쿠스 뮤탄스(Strepococcus mutans)에 대해 50% 이상의 생장억제 활성과 50% 이상의 활성 산소종 억제 활성을 동시에 나타내는 것을 특징으로 하는 천연 추출물에 대한 것이다.The present invention relates to an extract having activity for the prevention and treatment of oral diseases, which is isolated from a natural material, and has a growth inhibitory activity of 50% or more and activity of 50% or more against Streptococcus mutans Wherein the extracts exhibit oxygen species inhibitory activity at the same time.
Description
본 발명은 천연물 소재로부터 분리한 구강질환 예방 및 치료용 활성을 가진 추출물에 관한 것으로서, 더욱 상세하게는, 스트렙토코쿠스 뮤탄스( Streptococcus mutans)에 대해 50% 이상의 생장억제 활성과 50% 이상의 활성 산소종 억제 활성을 동시에 나타내는 것을 특징으로 하는 천연 추출물에 대한 것이다.The present invention relates to a extract with the release oral disease preventive and therapeutic activity for from natural materials, and more particularly, Streptococcus mutans (Streptococcus mutans) or more than 50% growth inhibition and 50% of active oxygen for Lt; RTI ID = 0.0 > inhibitory < / RTI > activity.
사람의 입안(구강)에는 다양한 종류의 세균들이 군집을 형성하고 있다. 구강의 타액과 분비물에는 다양한 단백질이 존재하는데, 예를 들어 입안에는 라이소자임(Lysozyme)이라는 효소를 포함하고 있는 침이 지속적으로 분비되어 미생물을 제어하고 있지만, 영양분이 가득한 구강환경은 미생물 성장에 최적의 조건이 될 수 있기에 완전한 사멸을 유도하지는 못한다. 특히 구강의 혀나 치태(dental plaque)는 병원성 미생물들의 도피처로 이용되고 있다.In the human mouth (oral cavity), various kinds of bacteria form a cluster. There are various proteins in oral saliva and secretions. For example, in the mouth, a needle containing an enzyme called lysozyme is continuously secreted to control microorganisms. However, the nutrient-rich oral environment is most suitable for microbial growth It does not induce complete killing because it can be a condition. In particular, oral tongue and dental plaque (dental plaque) is used as a refuge of pathogenic microorganisms.
사람의 구강(oral cavity) 내에 생존하는 것으로 추측되는 미생물은 대략 600 내지 800종 이상으로 알려져 있고, 이 중 박테리아(bacteria)가 대부분을 차지하고 있지만, 고세균(archaea)이나 진핵미생물(fungi and yeast)도 많이 포함되어 있는 것으로 알려져 있다.The number of microorganisms suspected to survive in a human oral cavity is known to be about 600 to 800 or more, and most of them are bacteria, but archaea and fungi and yeast It is known to contain many.
이들 중 대부분은 무해한 일반세균이거나, 이들과 공생관계에 있는 미생물이지만, 일부의 미생물들은 기회 병원균(opportunistic pathogen)으로서, 치아우식증(dental cavities; 충치)과 치주질환(periodontal disease; 풍치)과 같은 질환의 원인이 된다.Most of these are harmless general bacteria or microorganisms that are in symbiotic relationship with them. However, some microorganisms are opportunistic pathogens, which are diseases such as dental cavities and periodontal disease .
치아우식증은, 플라크(dental plaque; 치태)를 형성하는 미생물들이 입 속의 영양분을 이용해 발효대사를 진행하여 젖산과 같은 다양한 유기산을 만들고 치아표면의 칼슘을 제거함으로써 유발된다. 상기 플라크는, 침 속에 있는 단백질이 치아에 얇은 막을 형성하고, 그 위에 연쇄상구균의 일종인 스트렙토코쿠스 소브리누스(Streptococcus sobrinus)균 및 스트렙토코쿠스 무탄스(Sterptococcus mutans)가 순서대로 부착해 바이오 필름(biofilm)을 형성함으로써 만들어지고, 푸조박테리움(Fusobacterium)에 의해 더욱 두꺼워진다.Dental caries is caused by microorganisms forming a plaque (dental plaque) through fermentation metabolism using nutrients in the mouth to make various organic acids such as lactic acid and to remove calcium from the tooth surface. In the plaque, the protein in the saliva forms a thin film on the tooth, and Streptococcus sobrinus strain and Streptococcus mutans , which are kind of streptococci, It is made by forming a film (biofilm) and thickened by Fusobacterium.
일단 치아표면 에나멜층이 유기산에 의해 파괴되면 그 아래의 치아층도 미생물이 분비한 단백질 분해효소에 의해 파괴되고 결국 치아우식증이 심해진다.Once the tooth surface enamel layer is destroyed by organic acids, the underlying dental layer is also destroyed by the proteolytic enzyme secreted by the microorganism, resulting in increased dental caries.
치주질환은 치주조직의 염증과 구조의 소실을 야기시키는 질환으로서, 풍치라고도 불린다. 구체적으로, 치주질환은 치아를 떠받들고 있는 치아주위의 조직에 염증이 생기는 질환으로서, 임상적으로 치은출혈(gingival bleeding)과 종창(swelling), 치주낭(periodontal pocket)의 형성 및 치조골의 파괴 등으로 치아의 상실을 가져오게 된다.Periodontal disease is a disease that causes inflammation of the periodontal tissue and loss of structure, also called taste. Specifically, periodontal disease is an inflammation of the surrounding tissues of the teeth that hold the teeth. It is clinically caused by gingival bleeding and swelling, formation of the periodontal pocket, and destruction of the alveolar bone. Resulting in loss of teeth.
이러한 치주질환의 주요 원인은 플라크로서, 이러한 플라크가 치주낭 내에 기계적으로 축적되면 주변에 존재하는 세균들의 서식처가 되며, 이러한 서식은 점차 호기성, 통기성, 그람 양성세균으로 점차 이행되어, 치주낭의 심부로 증식되게 된다. 이때 함께 증식된 혐기성 그람음성 세균의 독소 및 모든 산물은 직접 조직을 파괴하거나 면역계를 자극하여, 자극된 면역계에서부터 여러가지 작용에 의한 치주조직 파괴와 더불어 염증을 유발하게 된다.The major cause of periodontal disease is plaques. When these plaques are mechanically accumulated in the periodontal pockets, they become habitats of bacteria existing around them. These forms gradually migrate into aerobic, breathable, gram-positive bacteria, . At this time, the toxin and all products of the anaerobic Gram-negative bacteria that are multiplied together directly destroy the tissues or stimulate the immune system and cause irritation along with periodontal tissue destruction due to various actions from the stimulated immune system.
최근 연구보고에 의하면, 치주질환은 세균과 숙주(host)간 면역반응의 복잡한 상호작용의 결과로 조직손상이 야기되는 염증성 질환으로, 세균과 숙주에 의해 조절되는 조직 손상 경로에 활성 산소종(reactive oxygen species, ROS)도 관여하는 것으로 보고되고 있다.Recent studies have shown that periodontal disease is an inflammatory disease that causes tissue damage as a result of intricate interactions between bacterial and host immune responses and is associated with a pathogenesis of bacterial and host- oxygen species, ROS) are also reported to be involved.
숙주세포와 세균들은 활성 산소종에 의한 손상에 대한 방어기능으로서, 이를 제거하기 위한 항산화 방어체계를 갖추고 있다.Host cells and germs are defending against damage by reactive oxygen species and have an antioxidant defense system to eliminate them.
타액, 치은열구액(gingival crevicular fruid) 또는 혈장 내에 위치해 있는 주요한 세포외항산화제로는 아스코르빈산(ascorbic acid; Vitamin C), 요산(uric acid), α-토코페롤(α-tocopherol; Vitamin E), 카로티노이드(carotenoids; Vitamin A), 빌리루빈(bilirubin), 환원형 글루타치온(reduced glutathione), 트랜스페린 (transferrin), 락토페린(lactoferrin), 합토글라빈(haptoglobin) 등이 있다.The major extracellular antioxidants located in saliva, gingival crevicular fruid or plasma include ascorbic acid (Vitamin C), uric acid, α-tocopherol (Vitamin E) Carotenoids (Vitamin A), bilirubin, reduced glutathione, transferrin, lactoferrin, haptoglobin, and the like.
최근에는 치아우식증을 예방하기 위해서 구강 내 세균을 효과적으로 제거하면서 부작용 없이 안전하게 사용할 수 있는 생약추출물에 관한 연구가 활발하게 이루어지고 있는데, 이는 생약제제들이 이미 민간에서 다양한 목적으로 오래 전부터 사용되어 상대적으로 생체에 대한 안정성이 검증되었기 때문이다.Recently, studies on herbal medicine extracts that can be safely used without side effects and effective removal of bacteria in oral cavity have been actively carried out in order to prevent dental caries. This is because the herbal medicine preparations have already been used for many purposes in civilian for a long time, Because of its proven stability.
치아우식증의 주원인균인 스트렙토코쿠스 뮤탄스(S. mutans)에 대한 항균 작용을 나타내는 생약 추출물질로는 파고자, 자몽씨, 결명자, 당귀, 계피, 프로폴리스, 해조류, 코코아 폴리페놀, 플라보노이드, 손바닥 선인장 등이 알려져 있다. 또한 녹차, 홍차, 우롱차와 같은 차 추출물로부터 많은 폴리페놀이 분리되었으며, 이는 충치균이 방출하는 바이오필름 형성물질의 생성을 부분적으로 억제한다고 알려져 있다.Herbal extracts that exhibit antimicrobial activity against Streptococcus mutans , a major causative agent of dental caries, include Pagoja, Grapefruit, Cucumber, Angelica, Cinnamon, Propolis, Seaweed, Cocoa polyphenols, Flavonoids, Cacti, etc. are known. In addition, many polyphenols have been isolated from tea extracts such as green tea, black tea, and oolong tea, which are known to partially inhibit the production of biofilm-forming materials that are released by caries.
또한, 치주질환을 예방 또는 치료하기 위한 생약추출물은 몰약(Myrrha), 생백피 추출물, 상귀나리아 추출물, 옥수수의 추출물, 후박추출물, 은행잎 추출물, 대추추출물, 유백피추출물, 황련추출물, 생강추출물, 독활추출물 등이 알려져 있다.In addition, herbal medicine extracts for preventing or treating periodontal disease include myrrha, fresh mulberry extract, sanguinaria extract, corn extract, succulent extract, ginkgo biloba extract, jujube extract, milky white extract, And extracts of non-toxic extracts.
그러나, 종래의 천연추출물은 항균성만을 발휘하거나 또는 항산화 활성만을 발휘하므로, 구강질환 중 일부 질환의 예방 및 치료에만 국한되어 사용될 수 밖에 없는 문제가 있었다.However, the conventional natural extract has only antibacterial activity or exhibits only antioxidative activity, and thus has a problem that it is limited to the prevention and treatment of some diseases of oral diseases.
따라서, 구강질환 균과 치주질환 유발 활성 산소종에 대해 억제활성을 지닌 천연물 소재에 대한 필요성이 높은 실정이다.
Therefore, there is a high need for a natural material having an inhibitory activity against oral disease bacteria and periodontal disease-inducing active oxygen species.
본 발명은 상기와 같은 종래기술의 문제점과 과거로부터 요청되어온 기술적 과제를 해결하기 위해서, 구강질환 유발균주인 스트렙토코쿠스 뮤탄스( streptococcus mutans)의 생장억제 활성과 치주질환 유발인자인 활성 산소종 억제 활성을 동시에 갖는 천연 추출물을 제공하는 것을 목적으로 한다.The invention of streptococcus mutans (streptococcus mutans), oral disease causing strains in order to solve the technical problem, which has been requested from the problems, and of the prior art It is an object of the present invention to provide a natural extract having both a growth inhibitory activity and an active oxygen species inhibitory activity as a periodontal disease inducing factor.
따라서, 본 발명에 따른 천연 추출물은, 천연물 소재로부터 분리한 구강질환 예방 및 치료용 활성을 가진 추출물로서, 스트렙토코쿠스( Strepococcus mutans )에 대해 50% 이상의 생장억제 활성과 50% 이상의 활성 산소종 억제 활성을 동시에 나타내는 것을 특징으로 한다. Thus, as an extract with a natural extract, isolated from natural materials oral disease prevention and therapeutic activity in accordance with the present invention, streptococcus (Strepococcus mutans ) at a concentration of 50% or more and an active oxygen species-suppressing activity of 50% or more at the same time.
상기 50% 의 생장억제 활성과 50% 의 활성 산소종 억제 활성은 구강질환 예방 및 치료용 항균물질의 유효성, 즉, 항균성 판단을 위한 최소 농도로서, 식물추출물의 경우, 단일물질이 아닌 혼합물질로써 50% 이상의 세균 성장억제력이 확인될 때 항균성이 있는 것으로 판단한다.The 50% growth inhibitory activity and the 50% active oxygen species inhibitory activity are the minimum concentrations for judging the effectiveness of antimicrobial substances for the prevention and treatment of oral diseases, that is, antimicrobial activity. In the case of plant extracts, It is judged to be antimicrobial when the bacterial growth inhibitory power of 50% or more is confirmed.
상기 천연 추출물은 측백나무, 흑삼릉 및 감태나무로 이루어진 군에서 선택되는 천연물 소재로부터 분리된 것일 수 있다.The natural extract may be isolated from a natural material selected from the group consisting of a deciduous tree, a black gruel, and a rhizome.
상기 측백나무(Thuja orientalis L.)는 측백나무과에 속하는 상록침엽교목으로서 높이 25m, 지름 1m에 달하지만 관목상에 속하며, 작은 가지가 수직으로 벌어지는데, 이와 같이 가지가 수직으로 발달하므로 측백이라는 이름으로 불린다. 한방에서는 잎과 열매를 약재로 사용하는데, 잎의 약성은 양(凉)하고 신미고(辛微苦)하며, 지혈, 양혈, 수렴, 이뇨의 작용을 하여 토혈, 혈변, 대장염, 이질, 고혈압 등의 증상에 사용된다. 열매는 약성이 감(甘)하고 평(平)하며, 자양(滋養), 진정, 윤장(潤腸)의 효능이 있어 신경쇠약, 불면, 심계항진(心悸亢進), 신체허약, 변비 등의 치료제로 쓰인다.The cervical spine ( Thuja orientalis L.) is an evergreen needlework tree belonging to the Quercus mongolica family, 25 m high and 1 m in diameter, but belongs to the shrubs. Small branches grow vertically. Leaves and berries are used as medicinal materials in leaves. Leaves are weak and pleasant, and they act as hemostatic, blood, convergence, and diuretic, so they can be used as blood, blood, colitis, dysentery, hypertension Is used for the symptoms of. Fruit is sweet and flat and has the efficacy of nourishment, calm, and lump. It is a treatment for nervous breakdown, insomnia, heart palpitations, physical weakness and constipation. It is used.
또한, 흑삼릉( Sparganium stoloniferum )은 흑삼릉과의 여러살이풀로서, 연못가와 도랑에서 자라는데, 뿌리줄기가 옆으로 뻗으며 군데군데에서 줄기가 나온다. 뿌리, 줄기는 소종, 통경제, 최유제로 사용하는데, 흑삼릉의 덩이뿌리를 말린 한국약재인 삼릉(三稜)은 향이 없고 담담한 맛이지만 씹으면 약간 쏘며 아린 맛이 있다. 삼릉은 기를 보호하여 기의 흐름을 강하게 해주고 어혈을 없애는 작용이 있어 산후 어혈복통, 월경부조, 월경통, 월경폐색불통, 징가, 적취 등에 사용되며, 음식의 소화가 잘 안되는 식적을 제거시키는 작용도 있다. 약리작용으로 자궁외임신에 대한 유효성, 악성종양인 원발성간암에 대한 효과, 위암, 간암, 식도암, 자궁경부암, 유선암, 직장암, 폐암 등의 호전반응, 뇌혈전, 뇌전색, 뇌일혈로 인한 반신불수에 유효성을 보였고, 관상동맥질환의 심교통증 개선작용, 충수돌기 주위에도 효력을 나타냈다는 것이 알려져 있다.Further, Sparganium erectum (Sparganium stoloniferum ) is a multi-year-old herb with black ginseng, which grows in the pond and ditch, with rootstock extending sideways and stems emerging from some places. Roots and stems are used as extinction, tongkuk economy, and yujeju. The Korean herb medicine, which is dried in the roots of black ginseng roots, is a scentless and tender flavor, but it tastes slightly fried and chewed. It has a function to protect the flag and strengthen the flow of the flame and to remove the eosinophilia. It is used for postpartum hemorrhagic abdominal pain, menstrual relief, dysmenorrhea, menstrual occlusion, dysentery, ingestion, etc., . The efficacy of pharmacological effects on ectopic pregnancy, the effect on primary malignant tumors, gastric cancer, liver cancer, esophageal cancer, cervical cancer, breast cancer, rectal cancer and lung cancer, hemorrhage due to cerebral thrombosis, It has been known that the effect of coronary artery disease was also improved around the appendiceal process.
또한, 상기 감태나무는 산기슭의 양지에 자라는 녹나무과에 속하는 낙엽관목으로. 간자목 또는 백동백이라고도 한다. 한국본초도감에 의하면, 산호초(山胡椒)는 녹나무과의 갈잎떨기나무 감태나무(Lindera glauca Blume)의 열매이다. 맛은 맵고 성질은 따뜻하며, 효능은 중풍으로 말 못하는데 및 심복냉통에 사용한다. 중풍으로 갑자기 말을 못하는 증상에는 물에 넣고 달여서 복용하고 복부가 차서 일어나는 통증을 해소시킨다. 라고 기록되어 있다. 따라서, 민간에서는 풍습으로 인한 저림증, 마비, 관절통 및 근육통의 치료, 심복냉통의 치료, 외상출혈, 감기, 두통, 발혈, 악창 종독의 치료에 사용된다.In addition, the ginseng tree is a deciduous shrub belonging to the camphor tree which grows on the sunny side of the mountain. It is also referred to as cedarwood or white mugwort. According to the picture book of Korea, the coral reef (mountain pepper) is the fruit of the gabbia tree (Lindera glauca Blume). The taste is spicy, the quality is warm, and the efficacy is not in the sense of a paralysis, and it is used for the cold barrel of the thong. Symptoms that can not be said suddenly by paralysis, take in water and dalyeoseo to relieve pain caused by the abdomen. . Therefore, in the private sector, it is used in the treatment of lowering, paralysis, arthralgia and myalgia caused by customs, treatment of chest cold pain, trauma bleeding, cold, headache,
이와 같이, 측백나무, 흑삼릉 및 감태나무의 잎, 열매 등의 천연물 소재들은 다양한 약리활성이 보고되어 있지만, 아직까지 구강질환 유발균주에 대한 항균성과 치주질환 유발요소인 활성 산소종에 대한 항산화 효능을 동시에 가지는 약리활성에 대한 보고와 연구는 전무한 상태이다.Thus, although various pharmacological activities have been reported for natural materials such as leaves, fruits, and the like, the antimicrobial activity against the oral disease-causing strains and the antioxidative effect against the active oxygen species, At the same time, there have been no reports or studies on the pharmacological activity.
상기 천연물 소재는 측백나무의 잎, 열매 또는 줄기일 수 있고, 흑삼릉의 전초일 수 있으며, 감태나무의 줄기 또는 잎일 수 있다.The natural material may be a leaf, fruit or stem of a spruce tree, may be an outpost of a black gruel, or may be a stem or a leaf of a gentian tree.
스트렙토코쿠스 뮤탄스(Strepococcus mutans)에 대한 50% 이상의 생장억제 활성을 갖기 위한 측백나무의 잎, 열매 또는 줄기 추출물의 함량은, 최소 500 ㎍/㎖ 이상이다.The content of leaves, fruits or stem extracts of Cervus spp. To have a growth inhibitory activity over 50% against Streptococcus mutans is at least 500 μg / ml or more.
또한, 스트렙토코쿠스 뮤탄스(Strepococcus mutans)에 대한 50% 이상의 생장억제 활성을 갖기 위한 흑삼릉 전초 추출물의 함량은, 최소 100 ㎍/㎖ 이상이다.In addition, the content of the black ginseng seedling extract to have a growth inhibitory activity of 50% or more against Streptococcus mutans is at least 100 / / ml.
또한, 스트렙토코쿠스 뮤탄스(Strepococcus mutans)에 대한 50% 이상의 생장억제 활성을 갖기 위한 감태나무의 줄기 또는 잎 추출물의 함량은, 최소 100 ㎍/㎖ 이상이다.In addition, the content of the stem or leaf extract of Rhizoma leaves to have a growth inhibitory activity of 50% or more against Streptococcus mutans is at least 100 μg / ml or more.
또한, 50% 이상의 활성 산소종 억제 활성을 나타내는 측백나무의 잎, 열매 또는 줄기의 폴리페놀 함량이, 갈산(gallic acid)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg GAE/100g dw)으로 계산할 때, 395.27±24.39 mg GAE/100g dw 이고, 플라보노이드 함량이, 루틴(rutin)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg RE/100g dw)으로 계산하면 250.14±18.26 mg rutin/100g dw 이상일때, 50%의 DPPH(2,2-diphenyl-2-picrylhydrazyl hydrate) 라디칼 소거 활성을 나타내는 측백나무의 잎, 열매 또는 줄기 추출물의 함량은 33.10 ± 3.67 ㎍/㎖ 이상 이며, 50%의 ABTS(2,2`-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 라디칼 소거 활성을 나타내는 측백나무의 잎, 열매 또는 줄기 추출물의 함량은 62.96±5.23 ㎍/㎖ 이상이다.In addition, the polyphenol contents of the leaves, fruits or stems of the cabbage trees showing 50% or more active oxygen species inhibitory activity were measured by using a calibration curve by gallic acid, and the mg content per 100 g of dry sample (mg GAE / 100 g dw (Mg RE / 100 g dw) per 100 g of the dry sample using a calibration curve by rutin, the flavonoid content was 250.14 ± 18.26 mg (mg / 100 g dw), calculated as 395.27 ± 24.39 mg GAE / The content of leaves, fruit or stem extracts of the cabbage trees exhibiting 50% DPPH (2,2-diphenyl-2-picrylhydrazyl hydrate) radical scavenging activity is above 33.10 ± 3.67 ㎍ / ㎖ at rutin / The content of leaves, fruit or stem extracts of the cabbage trees showing the radical scavenging activity of ABTS (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) in the% is 62.96 ± 5.23 ㎍ / ㎖ or more.
이 때, 측백나무 잎, 열매 및 줄기 추출물 1㎎/㎖은 90.44±1.18%의 치주질환 염증에 의해 생성되는 아질산염(nitrite) 소거활성을 나타낸다.At this time, 1 mg / ml of the extract of Quercus serrata, Fruit and Stem shows nitrite scavenging activity produced by 90.44 ± 1.18% periodontal disease inflammation.
또한, 50% 이상의 활성 산소종 억제 활성을 나타내는 흑삼릉 전초의 폴리페놀 함량이, 갈산(gallic acid)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg GAE/100g dw)으로 계산할 때, 151.62±13.57mg GAE/100g dw 이고, 플라보노이드 함량이, 루틴(rutin)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg RE/100g dw)으로 계산하면 61.01±3.62 mg rutin/100g dw 이상일때, 50%의 DPPH 라디칼 소거 활성을 나타내는 흑삼릉 전초 추출물의 함량은 166.30±5.94 ㎍/㎖ 이상이며, 50%의 ABTS 라디칼 소거 활성을 나타내는 흑삼릉 전초 추출물의 함량은 155.76 ± 9.05 ㎍/㎖ 이상이다.The polyphenol content of the black ginseng outpost showing 50% or more active oxygen species inhibitory activity was calculated as mg content (mg GAE / 100 g dw) per 100 g of dry sample using a calibration curve with gallic acid, ± 13.57 mg GAE / 100 g dw and the flavonoid content was 61.01 ± 3.62 mg rutin / 100 g dw or more calculated as mg content (mg RE / 100 g dw) per 100 g of dry sample using a calibration curve by rutin , The content of the black ginseng seedling extract showing 50% DPPH radical scavenging activity was 166.30 ± 5.94 ㎍ / ㎖ or more and the content of black ginseng seedling extract showing 50% of ABTS radical scavenging activity was 155.76 ± 9.05 ㎍ / ㎖ or more.
이 때, 흑삼릉 전초 추출물 1㎎/㎖은 60.29±4.12%의 치주질환 염증에 의해 생성되는 아질산염(nitrite) 소거활성을 나타낸다.At this time, 1 mg / ml of black ginseng seed extract showed nitrite scavenging activity produced by 60.29 ± 4.12% periodontal disease inflammation.
또한, 50% 이상의 활성 산소종 억제 활성을 나타내는 감태나무의 줄기 또는 잎의 폴리페놀 함량이, 갈산(gallic acid)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg GAE/100g dw)으로 계산할 때, 189.70 ± 4.33 mg GAE/100g 이고, 플라보노이드 함량이 루틴(rutin)에 의한 검량곡선을 이용하여 건조시료 100g 당 mg 함량(mg RE/100g dw)으로 계산하면 67.50 ± 1.45 mg RE/100g dw 이상 일때, 50%의 DPPH 라디칼 소거 활성을 나타내는 감태나무 줄기 또는 잎의 추출물 함량은 28.45 ± 3.96 ㎍/㎖ 이상이며, 50%의 ABTS 라디칼 소거 활성을 나타내는 감태나무의 줄기 또는 잎의 추출물의 함량은 34.52±0.34 ㎍/㎖ 이상이다.In addition, the polyphenol content of the stem or leaf of Rhizopus japonicus, which exhibits more than 50% of active oxygen species inhibitory activity, is determined by using a calibration curve by gallic acid, and the mg content (mg GAE / 100 g dw) per 100 g of dry sample Calculated as 189.70 ± 4.33 mg GAE / 100 g and the flavonoid content was calculated as mg content (mg RE / 100 g dw) per 100 g of dry sample using a calibration curve by rutin, 67.50 ± 1.45 mg RE / 100 g dw , The content of extracts of the stem or leaf extracts of P. vivax showed 50% of DPTS radical scavenging activity of 28.45 ± 3.96 ㎍ / ㎖ and 50% of ABTS radical scavenging activity, 34.52 占 .34 占 퐂 / ml or more.
이 때, 감태나무 줄기 및 잎의 추출물 1㎎/㎖은 67.64±7.06%의 치주질환 염증에 의해 생성되는 아질산염(nitrite) 소거활성을 나타낸다.At this time, 1 mg / ml of extracts of Rhizopus japonicus and leaves showed nitrite scavenging activity produced by 67.64 ± 7.06% periodontal disease inflammation.
본 발명에 따른 천연 추출물은, 상기한 천연물 소재를 물 또는 알코올에 넣고 가열하여 추출물을 얻고, 상기 추출물을 농축함으로써 제조될 수 있다.The natural extract according to the present invention can be prepared by adding the above natural material to water or alcohol and heating to obtain an extract, and concentrating the extract.
예를 들어, 건조된 상기 측백나무의 천연물 소재 150g 정도를 추출병에 넣고 증류수를 부어 80 ~ 121℃의 온도로 5시간 3회 정도 추출하거나, 또는 건조 천연물 소재 150g을 95 ~ 99% 농도의 에탄올 또는 메탄올에 1 ~ 15배의 부피량으로 넣고 냉각콘덴서가 부착된 추출기에서 70 ~ 80℃로 12시간 정도 가열하여 추출한 추출액을 다시 감압 여과한 후, 고형분을 제거하고 여액을 냉각콘덴서가 달린 농축장치에서 바람직하게는 50 ~ 90 brix로 감압 농축한 후 동결 건조시킴으로써 제조될 수 있다. For example, about 150 g of the natural material of the dried bamboo tree is put into an extraction bottle, and distilled water is poured thereon to extract it at a temperature of 80 to 121 ° C for 5 hours three times, or 150 g of a dried natural material is dissolved in 95 to 99% Or methanol in a volume of 1 to 15 times, and the extract was heated at 70 to 80 ° C for 12 hours in an extractor equipped with a cooling condenser. The extracted liquid was again filtered under reduced pressure, and then the solid content was removed. The filtrate was concentrated with a condenser , Preferably 50 to 90 brix, followed by lyophilization.
상기한 천연 추출물은 구강질환 예방 및 치료제의 유효성분으로서, 제형에 관계없이 의약품으로 사용될 수 있고, 비제한적인 예로서, 액상치약, 구강청정제, 구강용 스프레이, 구강용 연고제, 구강용 바니쉬 등의 형태로 사용될 수 있다.The above-mentioned natural extracts can be used as medicines regardless of the formulations as an active ingredient of the oral disease prevention and treatment agent, and include, for example, liquid toothpaste, mouthwash, oral spray, Can be used.
이상의 설명과 같이, 본 발명에 따른 천연 추출물은 소정 농도에서 구강질환 유발균주인 스트렙토코쿠스 뮤탄스(Streptococcus mutans)에 대해 50% 이상의 생장억제 활성과 50% 이상의 활성 산소종 억제 활성을 동시에 나타내므로, 이를 유효성분으로 포함하는 의약품은 치아우식증 및 치주질환을 동시에 예방 및 치료할 수 있는 장점이 있다.As described above, the natural extract according to the present invention simultaneously exhibits a growth inhibitory activity of 50% or more and an active oxygen species inhibitory activity of 50% or more against Streptococcus mutans, which is an oral disease-causing strain, at a predetermined concentration , And the medicines containing it as an active ingredient have an advantage of being able to simultaneously prevent and treat dental caries and periodontal disease.
특히, 본 발명에 따른 천연 추출물을 치약, 구강청정제 등으로 사용하는 경우, 스트렙토코쿠스 뮤탄스(Streptococcus mutans)의 생장을 50% 이상의 억제되어, 세균침전물인 치태를 효율적으로 제거할 수 있는 장점이 있다.In particular, when the natural extract according to the present invention is used as a toothpaste, an oral cleaning agent, etc., the growth of Streptococcus mutans is inhibited by 50% or more, and the advantage of being able to efficiently remove plaque as a bacterial deposit have.
또한, 상기 의약품 등은 안전성이 입증된 천연추출물을 유효성분으로 사용하므로, 부작용이 극히 적은 장점이 있다.In addition, since the above-mentioned medicines and the like use natural extracts having proven safety as active ingredients, there is an advantage that side effects are extremely small.
도 1은 본 발명의 실시예에 따라 추출된 측백나무, 흑삼릉, 감태나무 추출물의 스트렙토코쿠스 뮤탄스(Streptococcus mutans)의 50% 생장억제 활성농도 결정을 보여주는 그래프이다.FIG. 1 is a graph showing the determination of the 50% growth inhibitory concentration of Streptococcus mutans in the extracts of Cryptomeria japonica, Black Ginseng, and Ganoderma lucidum extracted according to the embodiment of the present invention.
이하에서는 실시예 등을 참조하여 본 발명을 더욱 상술하지만, 본 발명의 범주가 그것에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to Examples and the like, but the scope of the present invention is not limited thereto.
<실시예 1>≪ Example 1 >
건조된 측백나무, 흑삼릉, 감태나무의 천연물 소재 150g을 추출병에 넣고 증류수를 부어 90℃의 온도로 5시간 3회 추출하였다. 추출액은 다시 워터만 종이 여과지로 감압 여과한 후, 고형분은 제거하고 나머지 액을 냉각콘덴서가 달린 농축장치에서 감압 농축하여 동결 건조하였다(90 brix).
150 g of natural material of dried cedar wood, black gruel, and ganoderma lucidum were placed in an extraction bottle, distilled water was poured, and the mixture was extracted three times at 90 ° C for 5 hours. The extract solution was filtered again with a filter paper made of water and paper, and the solid content was removed. The remaining solution was concentrated under reduced pressure in a condenser equipped with a cooling condenser and lyophilized (90 brix).
<실험예 1><Experimental Example 1>
상기 실시예 1에서 제조된 천연추출물을 이용하여 충치질환 유발세균의 생육저지 활성, 충치질환 유발세균에 대한 생장억제 활성농도를 결정하기 위한 실험을 진행하였다. 효능판정은 50%이상의 생장억제 효능을 나타내는 농도를 최소 농도로 판정하였다. 이는 예방 및 치료목적으로 사용되기 위한 세균의 최소 생장억제 활성 농도이다.Using the natural extracts prepared in Example 1, experiments were carried out to determine the growth inhibition activity of the bacteria causing dental caries disease and the growth inhibitory activity concentration of the dental disease-causing bacteria. The efficacy was determined as the minimum concentration indicating a growth inhibitory effect of 50% or more. This is the minimum inhibitory activity concentration of bacteria to be used for preventive and therapeutic purposes.
실험 세균으로서 구강질환 유발균인 스트렙토코쿠스 뮤탄스(Streptococcus mutans)는 KCTC(Korean Collection for Type Cultures)에서 동결 바이알(vial)로 분양 받은 Streptococcus mutans KCTC3065를 사용하였다. Streptococcus mutans , an oral disease-causing strain, was used as an experimental bacterium. Streptococcus mutans was purchased from Streptococcus mutans KCTC3065 was used.
스트렙토코쿠스 뮤탄스(Streptococcus mutans)는 뇌심장침출액(brain heart infusion)배지(Sheep brain and heart extract 37%)에 접종하여 37℃, 호기성 조건으로 20~24시간 배양하였다. 각각의 천연물의 구강질환 유발세균에 대한 50% 생장억제 활성농도(㎍/㎖)을 결정하기 위해 각각 천연추출물을 액체 배지에 첨가, 연속희석방법(serial dilution method)을 통해 0~500㎍/㎖ 농도의 범위로 희석하여 멸균하였다. 또한, 각각의 천연 추출물의 농도별로 첨가된 배지에 전배양된 각각의 세균을 분광광도계 OD600nm에서 2×106cell/㎖가 되도록 접종하여 각 균의 성장조건에서 배양하였다. 배양 후 분광광도계를 이용하여 접종 시와 배양 종료후의 OD600nm에서 흡광도를 측정하여 50% 생장억제 활성농도값(㎍/㎖)을 측정하였다. 그 결과를 하기 표 1에 표시하였다.
Streptococcus mutans were inoculated into brain heart infusion medium (Sheep brain and heart extract 37%) and cultured at 37 ° C under aerobic conditions for 20 to 24 hours. Natural extracts were added to the liquid medium to determine the 50% growth inhibitory activity concentration (쨉 g / ml) of the respective natural products against oral disease-causing bacteria, and 0 to 500 ㎍ / ml And then sterilized. Each of the bacteria pre-cultured in the medium supplemented with the concentration of each natural extract was inoculated at a density of 2 × 10 6 cells / ml at a OD 600 nm of a spectrophotometer and cultured under the growth conditions of each bacterium. After the incubation, the absorbance was measured at OD 600 nm at the time of inoculation and at the end of the culture using a spectrophotometer, and the 50% growth inhibitory activity concentration value (쨉 g / ml) was measured. The results are shown in Table 1 below.
[표 1] 스트렙토코쿠스 뮤탄스(Streptococcus mutans)에 대한 최소저해농도[Table 1] Minimum inhibitory concentration for Streptococcus mutans
상기 표 1에서 보는 바와 같이, 본 발명에 따른 각각의 추출물의 100 ~ 500 ㎍/㎖의 농도를 첨가하였을 경우, 구강질환 유발 세균인 스트렙토코쿠스 뮤탄스(Streptococcus mutans)의 생장이 억제됨을 알 수 있다. 실험에 사용한 시료가 완전히 정제되지 않은 추출물로 낮은 성장 저해 활성을 나타내었지만 정제 할 경우 이보다 낮은 농도에서 성장 저해 활성을 나타낼 것으로 예측된다. 이는 구강 위생 제품 생산 시, 낮은 농도에서도 구강질환 유발 세균의 생장을 억제함으로 적은 양을 첨가하더라도 효과적으로 구강질환 예방 및 치료 효과를 발휘할 수 있음을 의미한다. As shown in Table 1, when the concentration of each extract according to the present invention was 100 to 500 μg / ml , the growth of Streptococcus mutans , an oral disease-causing bacterium, was inhibited have. Although the sample used in the experiment was not completely purified, it showed low growth inhibitory activity but it would be expected to exhibit growth inhibitory activity at a lower concentration when purified. This means that the oral hygiene product can inhibit the growth of the oral disease-causing bacteria even at a low concentration, which means that the addition of a small amount can effectively prevent or treat oral diseases.
실험 결과는 3회 반복 측정 후 시료군 간의 유의성을 검증하였다. 다만, 상기와 같이 얻어진 각 천연물소재의 추출물은 식물의 채취 시기, 서식 장소 등 식물의 성장 환경에 따라 효능 함량이 달라 질 수도 있다.
The results of the experiment were verified after 3 repeated measurements. However, the extract of each natural material obtained as described above may vary in efficacy depending on the growth environment of the plant, such as the time of collection of the plant and the habitat.
<실험예 2> 총 폴리페놀 함량 및 총 플라보노이드 함량 측정≪ Experimental Example 2 > Measurement of total polyphenol content and total flavonoid content
실시예 1에서 제조된 천연추출물을 이용하여 총 폴리페놀 함량 및 총 플라보노이드 함량을 측정하였다.The total polyphenol content and total flavonoid content were measured using the natural extract prepared in Example 1.
폴리페놀은 항산화 효과가 있어 식품이나 의료 등에 응용되는 주요 물질로서 알려져 있다. 본 발명에 따른 천연 추출물 1 ㎎/㎖ 100 ㎕에 10% Na2CO3 100㎕를 첨가한 후 상온에서 5분간 정치(定置)하였다.Polyphenol has been known as a major substance for applications in foods and medical care because of its antioxidant effect. 100 쨉 l of 10% Na 2 CO 3 was added to 1 ㎎ / ml of the natural extract according to the present invention, and the mixture was allowed to stand at room temperature for 5 minutes.
상기 추출물 혼합액과 50% Folin-Ciocalteu 시약(Folin-ciocalteau s phenol reagent) 100 ㎕을 혼합하여 반응시키고 상온조건의 암실에서 60분간 보관한 후 분광광도계를 이용하여 725 nm에서 흡광도를 측정하였다. 갈산(gallic acid)를 0 ~ 1,000 ㎎/㎖의 농도로 제조하여 시료와 동일한 방법으로 분석하여 얻은 표준 검량선으로부터 시료추출물의 총 페놀 함량을 계산하였다.The extract mixture and 50% Folin-
모레노(Moreno) 방법(Ref. Nieva Moreno 2000)에 따라 천연 추출물 1 ㎎/㎖ 100㎕에 10% 염화 알루미늄(aluminum chloride) 100㎕를 첨가한 후 상온에서 5분간 정치한 후, 상기 추출물 혼합액과 1.0 M 초산 칼륨(potassium acetate) 100㎕을 혼합하여 반응시키고 상온조건에서 40분간 보관한 후 분광광도계를 이용하여 420 nm에서 흡광도를 측정하였다. Rutin을 표준물질로 하여 0 ~ 1,000 ㎎/㎖의 농도범위에서 얻어진 표준 검량선으로부터 추출물의 총 플라보노이드 함량을 계산하였다.100 쨉 l of 10% aluminum chloride was added to 1 ㎎ / ml of the natural extract according to the Moreno method (Ref. Nieva Moreno 2000), and the mixture was allowed to stand at room temperature for 5 minutes. M potassium acetate were mixed and reacted. After storage at room temperature for 40 minutes, the absorbance was measured at 420 nm using a spectrophotometer. The total flavonoid content of the extracts was calculated from standard calibration curves obtained at concentrations ranging from 0 to 1,000 mg / ㎖ using Rutin as a reference material.
성분의 함량은 식품의약안정청의 권고 사안에 따라 표준 시료인 갈산(gallic acid)과 루틴(rutin)으로부터 작성된 검량 곡선을 이용하여 건조시료 100g당 mg함량으로 표시하였다. 그 결과를 하기 표 2에 나타내었다.
The content of each ingredient was expressed as mg content per 100 g of dry sample using a calibration curve prepared from standard samples gallic acid and rutin according to the recommendation of Food and Drug Administration. The results are shown in Table 2 below.
[표 2] 총 폴리페놀 및 총 플라보노이드 함량 [Table 2] Total polyphenol and total flavonoid content
1. gallic acid에 의한 검량곡선을 이용한 건조시료 100g당 mg함량1. mg content per 100 g dry sample using calibration curve with gallic acid
2. rutin에 의한 검량곡선을 이용한 건조시료 100g당 mg함량
2. mg content per 100 g of dry sample using calibration curve by rutin
상기 표 2에서 보는 바와 같이, 본 발명에 따른 추출물의 총 폴리페놀과 총 플라보노이드의 함량은 측백나무에서 가장 많은 함유량을 갖는 것으로 확인되었다. 항산화 소재로서 측백나무 추출물이 흑삼릉 추출물, 감태나무 추출물보다 바람직함을 확인할 수 있었다.As shown in Table 2, the content of total polyphenols and total flavonoids of the extract according to the present invention was found to be the largest in the cabbage trees. As the antioxidant material, it was found to be more desirable than the extracts of black ginseng and ginseng extract.
실험 결과는 3회 반복 측정 후 평균±표준편차로 나타내었으며, 시료군 간의 유의성을 검증한 후 p<0.05 수준에서 던칸(Duncan)의 다중범위 검증법(multiple range test)에 따라 분석하였다. 다만, 상기와 같이 얻어진 각 천연물소재의 추출물은 식물의 채취 시기, 서식 장소 등 식물의 성장 환경에 따라 효능 함량이 달라 질 수도 있다.
The test results were expressed as mean ± SD after 3 repetitions. The significance of each sample was verified and analyzed by Duncan's multiple range test at p <0.05. However, the extract of each natural material obtained as described above may vary in efficacy depending on the growth environment of the plant, such as the time of collection of the plant and the habitat.
<실험예 3> DPPH 라디칼 소거능 및 ABTS 라디칼을 이용한 총 항산화력 측정<Experimental Example 3> Measurement of total antioxidant capacity using DPPH radical scavenging ability and ABTS radical
실시예 1에서 제조된 천연추출물을 이용하여, 활성 산소종의 활성 저해 효능 확인을 위한 자유라디칼 소거 활성측정을 위해 DPPH 항산화 활성 테스트와 ABTS 항산화 활성 테스트를 수행하였다.DPPH antioxidant activity test and ABTS antioxidant activity test were performed for measuring the free radical scavenging activity for confirming the activity inhibition activity of the active oxygen species using the natural extract prepared in Example 1.
DPPH 라디칼 소거능 측정은 0.2 mM DPPH(2,2-diphenyl-2-picrylhydrazyl hydrate) 60㎕와 농도별로 준비한 시료 60㎕를 혼합하여 상온의 암실에서 15~30분간 반응시킨 후 분광광도계를 이용하여 517 nm에서 흡광도를 측정하였다.The DPPH radical scavenging activity was measured by mixing 60 μl of 0.2 mM DPPH (2,2-diphenyl-2-picrylhydrazyl hydrate) and 60 μl of the prepared sample in a dark room at room temperature for 15 to 30 minutes. Then, using a spectrophotometer, The absorbance was measured.
ABTS 라디칼을 이용한 총 항산화력 측정은 과항산 칼륨(potassium persulfate)와의 반응에 의해 생성된 ABTS(2,2`-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 유리 라디칼이 추출물 내의 항산화 물질에 의해 제거되어 라디칼 특유의 색인 청록색을 탈색시키는 방법으로 수행되었다.The total antioxidant activity of ABTS radicals was determined by measuring the antioxidant activity of ABTS (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) free radicals produced by the reaction with potassium persulfate To discolor the cyan color of the radical-specific index.
7.4 mM ABTS와 2.6 mM potassium persulfate를 동량 혼합하여 암실에서 15~24시간 반응시킨다. 사용직전에 734 nm에서 흡광도 0.7(±0.03)로 증류수를 이용하여 희석한다. 희석액 950㎕에 50㎕ 시료를 첨가하여 혼합한 다음, 실온에서 10분간 반응시킨 후 734 nm에서 흡광도를 측정하였다. Equal amounts of 7.4 mM ABTS and 2.6 mM potassium persulfate are mixed and reacted in the dark for 15-24 hours. Immediately before use, dilute with distilled water to 73 (± 0.03) absorbance at 734 nm. 50 μl of sample was added to 950 μl of the diluted solution, and the mixture was reacted at room temperature for 10 minutes, and the absorbance was measured at 734 nm.
DPPH 테스트의 항산화 활성의 정도는 50% DPPH 라디칼 소거활성 농도인 SC50 값으로 표시하고, ABTS 테스트의 항산화 활성의 정도는 50% ABTS 라디칼 소거활성 농도인 SC50 값으로 표시하였다. 대조군으로 사용된 갈산(gallic acid)의 DPPH SC50 값은 9.07 ± 0.2 ㎍/㎖로 측정되었으며, ABTS SC50 값은 4.96 ± 0.28 ㎍/㎖로 측정되었다.The degree of antioxidant activity in the DPPH test is degree of antioxidant activity of a display and, ABTS test the 50% DPPH radical scavenging activity concentration of SC 50 values are expressed as 50% ABTS radical scavenging activity concentration of 50 SC value. The DPPH SC 50 value of gallic acid used as a control was 9.07 ± 0.2 ㎍ / ㎖, and the ABTS SC 50 value was 4.96 ± 0.28 ㎍ / ㎖.
또한, 치주질환 염증 치료 효과를 확인하기 위해 항산화 소재로서의 활용 가능성을 보이는 천연 추출물의 아질산염 소거능 테스트를 수행하였다. In addition, nitrite scavenging ability test of natural extracts showing possibility of using as antioxidant material was conducted to confirm the therapeutic effect of periodontal disease inflammation.
아질산염(nitrite) 소거 활성은 카토(Kato)등의 방법(Ref. Kato H, Lee IE 1987)으로 수행 하였다. 1 mM NaNO2 40㎕에 천연물 추출물 40㎕를 첨가한다. 0.1 N HCl을 이용하여 pH 1.2로 보정한 후 37℃에서 1시간 반응시킨다. 2% acetic acid 1㎖와 Griess 시약 100㎕을 첨가한 후 상온에서 15분간 반응시킨 뒤 520 nm에서 흡광도를 측정하였다. 그 결과를 하기 표 3에 나타내었다. 치주질환 염증에 의해 생성되는 아질산염(nitrite) 소거활성의 대조군으로 vitamin C(ascorbic acid) 1㎎/㎖을 이용하였고, 대조군인 vitamin C의 소거 활성은 96.64±0.26%로 확인 되었다.
The nitrite scavenging activity was performed by the method of Kato et al. (Ref. Kato H, Lee IE 1987). Add 40 μl of natural product extract to 40 μl of 1 mM NaNO 2 . After adjusting to pH 1.2 with 0.1 N HCl, react at 37 ° C for 1 hour. 1 ml of 2% acetic acid and 100 μl of Griess reagent were added, reacted at room temperature for 15 minutes, and absorbance was measured at 520 nm. The results are shown in Table 3 below. Vitamin C (ascorbic acid) 1mg / ㎖ was used as a control for the nitrite scavenging activity produced by periodontal disease inflammation and the scavenging activity of vitamin C as a control group was found to be 96.64 ± 0.26%.
[표 3] 항산화 효능 평가[Table 3] Antioxidant efficacy evaluation
상기 표 3에서 보는 바와 같이, 본 발명에 따른 DPPH와 ABTS를 이용한 항산화 효능 측정 실험에서 측백나무와 감태나무에서 우수한 항산화 효능을 확인 할 수 있었으며, 아질산염 소거 활성은 측백나무가 우수하였다.As shown in Table 3, the antioxidant activity of DPPH and ABTS according to the present invention was excellent in antioxidant activity in the Quercus serrata and Quercus serrata, and the nitrite scavenging activity of Quercus serrata was superior.
상기 표 2 및 3에서 보는 바와 같이, 본 발명에 따른 천연물 소재인 측백나무, 흑삼릉 및 감태나무로 이루어진 군에서 선택하여 사용한 추출물은 스트렙토코쿠스 뮤탄스(Streptococcus mutans)에 대해 50% 생장억제 활성을 나타내는 동시에 50%의 활성 산소종 억제 활성을 나타내었으며, 특히 측백나무가 바람직한 항산화 효능을 나타내었다.As shown in Tables 2 and 3, the extracts selected from the group consisting of the natural wood materials of the present invention, which are selected from the group consisting of Quercus serrata, Black ginseng and Rhodophyta, have a 50% growth inhibitory activity against Streptococcus mutans And 50% of the active oxygen species inhibitory activity, respectively.
실험 결과는 3회 반복 측정 후 평균eee표준편차로 나타내었으며, 시료군 간의 유의성을 검증한 후 p<0.05 수준에서 던칸(Duncan)의 다중범위 검증법(multiple range test)에 따라 분석하였다.Experimental results were expressed as mean eee standard deviation after 3 repetitions. The significance of each sample was tested and analyzed by Duncan's multiple range test at p <0.05.
본 발명이 속한 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.Those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130121685A KR101426238B1 (en) | 2013-10-14 | 2013-10-14 | Herbal Extract For Preventing and Treating Disease of Oral Cavity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130121685A KR101426238B1 (en) | 2013-10-14 | 2013-10-14 | Herbal Extract For Preventing and Treating Disease of Oral Cavity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120031773A Division KR20130109765A (en) | 2012-03-28 | 2012-03-28 | Herbal extract for preventing and treating disease of oral cavity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130121070A KR20130121070A (en) | 2013-11-05 |
KR101426238B1 true KR101426238B1 (en) | 2014-08-05 |
Family
ID=49851468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130121685A KR101426238B1 (en) | 2013-10-14 | 2013-10-14 | Herbal Extract For Preventing and Treating Disease of Oral Cavity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101426238B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108785392B (en) * | 2017-04-28 | 2021-04-16 | 江苏凯吉生物科技有限公司 | Application of sweet osmanthus extract in preparation of IDO inhibitor |
-
2013
- 2013-10-14 KR KR1020130121685A patent/KR101426238B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Chinese Journal of Spectroscopy Laboratory, 5, 023. (2010) * |
Fine Chemicals 6, 010. (2010) * |
Journal of Fujian Forestry Science and Technology 3, 040. (2008) * |
Also Published As
Publication number | Publication date |
---|---|
KR20130121070A (en) | 2013-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
CN110519997B (en) | Method for relieving gingivitis and periodontitis by antibiotic, antioxidant, antiinflammatory, periodontal bone loss inhibiting and regeneration of tooth Zhou Gu of Moringa oleifera leaf extract and eucommia ulmoides extract complex | |
US20080069783A1 (en) | Oral cavity cleaning composition | |
KR101663978B1 (en) | Oral composition containing fermented herb extract for anti- gingivitis | |
KR102594674B1 (en) | Oral composition comprising herbal complex | |
KR102572961B1 (en) | Compositions for preventing, improving or treating periodontal disease containing dendropanax morbifera lev. extracts | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR100770140B1 (en) | A Composition for Wet Tissue | |
KR101506858B1 (en) | Herbal Extract for Having an Antibacterial and Antibiofilm Effect on Oral Pathogen | |
KR20060083915A (en) | Oral hygiene composition comprising extract of zanthoxylum schinifolium and manufacturing method thereof | |
KR102162661B1 (en) | Toothpaste Composition Comprising Rosa Canina Extract | |
KR101426238B1 (en) | Herbal Extract For Preventing and Treating Disease of Oral Cavity | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR20130109765A (en) | Herbal extract for preventing and treating disease of oral cavity | |
KR101365352B1 (en) | Composition for treating oral disease and inhibiting halitosis comprising the extract of Alder tree | |
KR102481102B1 (en) | Antibacterial composition containing starfish extract and cinnamon extract as active ingredients | |
KR102247777B1 (en) | Cosmetic composition containing the extracts of natural substances, Lindera strychnifolia, Albizia julibrissin and Castanea crenata, for improvement of scalp environment | |
KR101063351B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR102100989B1 (en) | Method for producing inner beauty beverage using Chrysanthemum zawadskii and fermeted Rhus verniciflua | |
KR102061622B1 (en) | Composition including mori folium extracts for antioxidant activation and anti-inflammatory | |
KR102690551B1 (en) | Composition for preventing, improving or treating of oral diseases comprising extract of Sarcodon aspratus as effective component | |
KR102156438B1 (en) | Composition for relieving and improving acute facial pain | |
KR20190136199A (en) | Drink composition comprising Moringa-fermentation product | |
KR102214621B1 (en) | Functional food composition containing black kelp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
FPAY | Annual fee payment |
Payment date: 20170526 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180517 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190520 Year of fee payment: 6 |